c-Met Recombinant Mouse Monoclonal Antibody [A9A4-R]
CAT:
992-HA601122
Size:
100 µL
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
![c-Met Recombinant Mouse Monoclonal Antibody [A9A4-R] - image 1](/gentaur-product-1.webp)
c-Met Recombinant Mouse Monoclonal Antibody [A9A4-R]
- Description: c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing. Hepatocyte growth factor/Scatter Factor (HGF/SF) and its splicing isoform (NK1, NK2) are the only known ligands of the MET receptor. MET is normally expressed by cells of epithelial origin, while expression of HGF/SF is restricted to cells of mesenchymal origin. When HGF/SF binds its cognate receptor MET it induces its dimerization through a not yet completely understood mechanism leading to its activation. Abnormal MET activation in cancer correlates with poor prognosis, where aberrantly active MET triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). MET is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express MET, which allows these cells to grow invasively in order to generate new tissues in an embryo or regenerate damaged tissues in an adult. However, cancer stem cells are thought to hijack the ability of normal stem cells to express MET, and thus become the cause of cancer persistence and spread to other sites in the body. Both the overexpression of Met/HGFR, as well as its autocrine activation by co-expression of its hepatocyte growth factor ligand, have been implicated in oncogenesis. Various mutations in the MET gene are associated with papillary renal carcinoma.
- Product Name Alternative: AUTS9 antibody c met antibody D249 antibody Hepatocyte growth factor receptor antibody HGF antibody HGF receptor antibody HGF/SF receptor antibody HGFR antibody MET antibody Met proto oncogene antibody Met proto oncogene tyrosine kinase antibody MET proto oncogene, receptor tyrosine kinase antibody Met proto-oncogene (hepatocyte growth factor receptor) antibody Met proto-oncogene antibody Met protooncogene antibody MET_HUMAN antibody Oncogene MET antibody Par4 antibody Proto-oncogene c-Met antibody RCCP2 antibody Scatter factor receptor antibody SF receptor antibody Tyrosine-protein kinase Met antibody
- Abbreviation: MET
- CAS Number: 9000-83-3
- Swiss Prot: P08581 Human
- Cellular Locus: Membrane; Secreted.
- Host: Mouse
- Species Reactivity: Human
- Immunogen: Synthetic peptide within human Met aa 1,341-1,390 / 1,390.
- Isotype: IgG1
- Clone: A9A4-R
- Conjugation: Non-conjugated
- Type: Recombinant Mouse monoclonal Antibody
- Applications: WB, IHC-P
- Positive Control: A549 cell lysate, HepG2 cell lysate, HT-29 cell lysate, Hela cell lysate, LO2 cell lysate, human lung adenocarcinoma tissue.
- Concentration: 1 mg/mL
- Dilution: WB: 1:500 ;IHC-P: 1:400
- Purity: Protein A affinity purified.
- Form: Liquid
- Buffer: PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
- Molecular Weight: Predicted band size: 156 kDa
- Storage Conditions: Store at +4°C after thawing. Aliquot store at -20°C. Avoid repeated freeze/thaw cycles.
- Recombinant Antibody: Yes